Galderma
Rebranded from Nestlé Skin Health, Galderma debuted in October 2019 as the world’s largest independent global dermatology company, following the completion of the 10.2 billion Swiss francs ($10.25 billion) acquisition by a group of investment funds..
The company is present in more than 100 countries with an extensive product portfolio to treat a range of dermatological conditions.
Galderma's chief executive is Flemming Ornskov, who previously led the transformation of biopharmaceutical company Shire to become the global leader in rare diseases.
The new owners intend to advance the current direction taken by Galderma’s management and focus on accelerating growth further by building on the company’s leading market positions and brands in a sector benefiting from strong innovation and demographic trends.
Latest Galderma News & Features
21 March 2024
30 November 2023
13 October 2023
3 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze